bluebird bio Inc American Society of Hematology (ASH) Data Review - Call Transcript
Good evening, everyone. Welcome to the bluebird bio 2019 ASH Conference Call. We are excited to be discussing the clinical data we presented at ASH in our transfusion-dependent beta thalassemia and sickle cell disease and multiple myeloma program as well as top line data from the registration-enabling KarMMa study in multiple myeloma that was announced on Friday. Press releases on these data can be found on the Investor Relations section of our website.
Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties, and involve a number of risk factors that could cause actual results to differ materially from projected results; in particular, statements that include, but are not limited to, the risks that any one or more of our product candidates will not be successfully developed, approved or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
